Citigroup Inc Absci Corp Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Absci Corp stock. As of the latest transaction made, Citigroup Inc holds 63,942 shares of ABSI stock, worth $190,547. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,942

Previous 17,587 263.58%

Holding current value

$190,547

Previous $54,000 351.85%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.97 - $4.49 $137,674 - $208,133	46,355 Added 263.58%	63,942 $244,000
Q2 2024 Aug 12, 2024	SELL	$2.92 - $6.58 $141,549 - $318,972	-48,476 Reduced 73.38%	17,587 $54,000
Q1 2024 May 10, 2024	SELL	$3.41 - $5.74 $560,430 - $943,363	-164,349 Reduced 71.33%	66,063 $375,000
Q4 2023 Feb 09, 2024	BUY	$1.15 - $4.79 $246,787 - $1.03 Million	214,598 Added 1357.01%	230,412 $967,000
Q3 2023 Nov 09, 2023	BUY	$1.28 - $2.41 $18,149 - $34,171	14,179 Added 867.22%	15,814 $20,000
Q2 2023 Aug 10, 2023	BUY	$1.17 - $2.03 $679 - $1,179	581 Added 55.12%	1,635 $2,000
Q1 2023 May 11, 2023	SELL	$1.58 - $3.41 $995 - $2,148	-630 Reduced 37.41%	1,054 $1,000
Q4 2022 Feb 09, 2023	SELL	$2.0 - $3.58 $34,536 - $61,819	-17,268 Reduced 91.11%	1,684 $3,000
Q3 2022 Nov 10, 2022	SELL	$2.95 - $4.83 $13,401 - $21,942	-4,543 Reduced 19.34%	18,952 $59,000
Q2 2022 Aug 10, 2022	SELL	$3.13 - $8.83 $26,802 - $75,611	-8,563 Reduced 26.71%	23,495 $78,000
Q1 2022 May 12, 2022	SELL	$5.87 - $9.46 $32,020 - $51,604	-5,455 Reduced 14.54%	32,058 $271,000
Q4 2021 Feb 10, 2022	BUY	$7.88 - $18.03 $282,899 - $647,295	35,901 Added 2227.11%	37,513 $308,000
Q3 2021 Nov 10, 2021	BUY	$10.37 - $30.29 $16,716 - $48,827	1,612 New	1,612 $19,000

Others Institutions Holding ABSI

# of Institutions

128

Shares Held

59.3M

Call Options Held

255K

Put Options Held

93.6K

View Full List

About Absci Corp

Ticker ABSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 92,843,504
Market Cap $277M
Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process....

More about ABSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account